Evidence map›Paper›PMID 36741102›Full record

ArticleHeart international2022

Can Percutaneous Coronary Intervention Revive a Failing Heart?

Saad M Ezad, Matthew Ryan, Divaka Perera

2 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in Heart international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 69% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00023595 phase3completednot on this map

Surgical Treatment for Ischemic Heart Failure (STICH)

TypeinterventionalSponsorDuke UniversityRan2002 to 2015Enrolled2,136ConditionsCardiovascular Diseases, Coronary Disease, Heart Failure, Congestive, Heart DiseasesArmsCABG surgery plus MED, Active Medication Alone, CABG plus MED and SVR
NCT01920048 nacompletednot on this map

REVascularisation for Ischaemic VEntricular Dysfunction (REVIVED): a Randomized Comparison of Percutaneous Coronary Intervention (With Optimal Medical Therapy) Versus Optimal Medical Therapy Alone for Treatment of Heart Failure Secondary to Coronary Disease

TypeinterventionalSponsorKing's College LondonRan2013 to 2022Enrolled700ConditionsIschemic CardiomyopathyArmsPercutaneous Coronary Intervention, Drug Therapy for Heart Failure, Device Therapy for Heart Failure
3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Saad M EzadBritish Heart Foundation Centre of Research Excellence and NIHR Biomedical Research Centre at the School of Cardiovascular Medicine and Sciences, King's College London, London, UK.
Matthew RyanBritish Heart Foundation Centre of Research Excellence and NIHR Biomedical Research Centre at the School of Cardiovascular Medicine and Sciences, King's College London, London, UK.
Divaka PereraBritish Heart Foundation Centre of Research Excellence and NIHR Biomedical Research Centre at the School of Cardiovascular Medicine and Sciences, King's College London, London, UK.
British Heart Foundation · GBKing's College London · GB

Funding

British Heart Foundation FS/CRTF/21/24118
6 · The paper itself

Abstract

Coronary artery disease (CAD) remains the most common cause of heart failure with reduced ejection fraction; despite its prevalence, there is limited evidence to guide physicians in managing patients with CAD with percutaneous revascularization. The REVIVED-BCIS2 trial (ClinicalTrials.gov identifier: NCT01920048) represents the first randomized trial to assess the value of percutaneous coronary intervention in addition to optimal medical therapy in patients with ischaemic left ventricular systolic dysfunction and stable CAD. In this article, we review the results of the REVIVED-BCIS2 trial and compare them to the ClinicalTrials.gov Identifier: NCT00023595 trial (ClinicalTrials.gov Identifier: NCT00023595), which investigated the benefit of surgical revascularization on such patients. Finally, we suggest a pathway for physicians managing patients with ischaemic left ventricular systolic dysfunction based on the current evidence and highlight potential avenues for future research.

Indexed as

Heart failureischaemic cardiomyopathyleft ventricular systolic dysfunctionpercutaneous coronary interventionpercutaneous coronary revascularizationrandomized clinical trialviability

Identifiers

PMID36741102
PMCPMC9872779
OpenAlexW4312801253

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.